(via TheNewswire)
Vancouver, British Columbia – TheNewswire - January 27, 2026 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF), (the “Company” or “MindBio”), a biotechnology company that conducts clinical health research and has developed a world first AI prediction tool for drug and alcohol intoxication detection by a simple analysis of the voice, is pleased to announce the Company is targeting the global digital health diagnostics market with a first mover advantage in using speech as a diagnostic tool in drug and alcohol intoxication detection.
The voice is a powerful biomarker that can be used to assess and predict internal health and disease states. The Company uses sophisticated machine learning models, developed during years of clinical trials, to analyse voice data and make predictions that are clinically meaningful and useful in a variety of consumer and enterprise situations.
The Company has developed and commercialised a technology, activated by a simple analysis of the voice and powered by AI to predict drug and alcohol intoxication. The Company has amassed large amounts of data from drug and alcohol clinical trials and has developed proprietary algorithms as the basis for its prediction technologies with remarkable accuracy for the detection of alcohol and hallucinogenic drugs.
The Company is currently showcasing its technology throughout the USA. The Company’s core technology can reliably predict intoxication with hallucinogens and alcohol by analysing voice. The Company plans to expand its algorithms to be able to detect other prohibited drugs that are difficult to detect particularly at scale and volume and require specialised equipment, with MindBio’s solution provided by a simple analysis of the voice.
The voice analytics solution being developed by MindBio is a revolutionary innovation for intoxication detection in workplace environments, particularly where drug and alcohol testing is mandated by regulators, such as the mining industry, aviation and construction and where high volume testing at scale for a variety of drugs and alcohol presents major challenges for management, is time consuming and expensive.
In a world first, MindBio has developed an AI model that uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The technology goes further to estimate actual blood alcohol concentration levels.
The Company is developing an enterprise version and new platform level technology for health prediction using the human voice and is expanding its drug and alcohol intoxication technology for use in workplace environments, call centres, mental health and law enforcement and the Company hopes to make announcements about the progress of the new technology, new products and markets and potential commercial applications, shortly.
The Company’s CEO Justin Hanka said, “The digital health diagnostics market represents a significant opportunity for MindBio to leverage its diagnostics technology with a first mover advantage in speech analytics for drug and alcohol intoxication detection”.
For further information, please contact:
Justin Hanka, Chief Executive Officer
61 433140886
justin@mindbiotherapeutics.com
About MindBio Therapeutics
MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) is a biotechnology company headquartered in Vancouver, British Columbia, that for several years has been conducting drug and alcohol research and has created health prediction technologies using AI and machine learning. The Company has expertise in using speech analytics as a prediction tool for drug and alcohol intoxication and has created a world first voice and AI powered prediction model for drug and alcohol intoxication for use in consumer and enterprise situations. The Company is developing a comprehensive enterprise platform using voice and powered by AI for use in detecting drug and alcohol intoxication in workplaces, law enforcement, mental health and telehealth.
Cautionary Note Concerning Forward-Looking Statements:
The press release contains "forward-looking statements" within the meaning of applicable securities laws. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "budget," "believe," "project," "estimate," "expect," "scheduled," "forecast," "strategy," "future," "likely," "may," "to be," "could," "would," "should," "will" and similar references to future periods or the negative or comparable terminology, as well as terms usually used in the future and conditional. Forward-looking statements are based on assumptions as of the date they are provided. However, there can be no assurance that such assumptions will reflect the actual outcome of such items or factors.
Additionally, there are known and unknown risk factors that could cause the Company's actual results and financial conditions to differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important risk factors that could cause actual results and financial conditions to differ materially from those indicated in the forward-looking statements, include among others: general economic, market and business conditions in Canada and Australia; market volatility; unforeseen delays in timelines for any of the transactions or events described in this press release. All forward-looking information is qualified in its entirety by this cautionary statement.
The Company disclaims any obligation to revise or update any such forward-looking statement or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
Neither the Canadian Securities Exchange nor its Regulation Service Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Copyright (c) 2026 TheNewswire - All rights reserved.